Latest News and Press Releases

TEL AVIV, Israel, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD) today announced financial results for the three and nine months ended September 30, 2017, and provided a corporate...

TEL AVIV, Israel, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) today announced financial results for the three and six months ended June 30, 2017, and provided a corporate update. ...

TEL AVIV, Israel, June 23, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical...

Company Adds Two Directors to the Board Company to Continue Strategic Alternatives Process to Maximize Value for All Shareholders TEL AVIV, Israel, June 12, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd....

TEL AVIV, Israel, May 30, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) today announced financial results for the three months ended March 31, 2017, and provided a corporate update. First...

Dr. Yaron Daniely to Step Down as Chief Executive Officer, Effective May 31, 2017 David Baker Named Interim Chief Executive Officer Dr. Daniely to Remain on Board of Directors and be Appointed...

TEL AVIV, Israel, May 05, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical...

The Board Will Defend Shareholders from Opportunistic Takeover of the Company Believes Brosh Capital's Request Does Not Comply With Alcobra's Articles of Association TEL AVIV, Israel, April 24,...

Brosh Capital’s Request Does Not Comply With Alcobra’s Articles of Association Company Addresses Brosh Capital’s Misinformed Views   TEL AVIV, Israel, April 05, 2017 (GLOBE NEWSWIRE) --...

TEL AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system...